Barclays on U.S. Specialty Pharmaceuticals: Model Adjustments on MYL, PRX, TEVA, & WCRX
Tweet Send to a FriendGet Alerts MYL Hot Sheet
Price: $31.48 -1.22%
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade MYL Now!
Barclays on U.S. Specialty Pharmaceuticals: Model Adjustments
For Mylan (NYSE: MYL), analyst, Douglas D. Tsao, said, "We are adjusting our 2012 spending trends in order to allow for a smoother SG&A and R&D progression, resulting in higher spend in 1Q and lower spend in 3Q...Our revised 2012 EPS quarterly estimates are as follows: 1Q12 EPS estimate of $0.49 (vs previous $0.52); 2Q12 EPS estimate of $0.56 (vs previous $0.58); 3Q12 EPS estimate of $0.73 (vs previous $0.72); and 4Q12 EPS estimate of $0.60 (unchanged). (FY12 EPS estimate lowered from $2.43 to $2.39)
Tsao on Par Pharmaceutical (NYSE: PRX): "We are raising our Par market share assumptions on generic Provigil in 2Q12 & 3Q12 to 40% from previous 20%, increasing our 2012 EPS estimate to $3.75 from $3.22 previously."
Teva Pharma (Nasdaq: TEVA): "1Q12 EPS estimate of $1.42 (vs previous $1.48);
2Q12 EPS estimate of $1.34 (vs previous $1.38); 3Q12 EPS estimate of $1.34 (vs
previous $1.32); and 4Q12 EPS estimate of $1.46 (vs previous $1.39)." (FY12 remains $5.57)
Warner Chilcott (Nasdaq: WCRX): "Following a review of our model, we are revising our 2012 EPS estimate to $3.68 (vs previous $3.64), with changes stemming from slight tweaks to our cost assumptions."
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For Mylan (NYSE: MYL), analyst, Douglas D. Tsao, said, "We are adjusting our 2012 spending trends in order to allow for a smoother SG&A and R&D progression, resulting in higher spend in 1Q and lower spend in 3Q...Our revised 2012 EPS quarterly estimates are as follows: 1Q12 EPS estimate of $0.49 (vs previous $0.52); 2Q12 EPS estimate of $0.56 (vs previous $0.58); 3Q12 EPS estimate of $0.73 (vs previous $0.72); and 4Q12 EPS estimate of $0.60 (unchanged). (FY12 EPS estimate lowered from $2.43 to $2.39)
Tsao on Par Pharmaceutical (NYSE: PRX): "We are raising our Par market share assumptions on generic Provigil in 2Q12 & 3Q12 to 40% from previous 20%, increasing our 2012 EPS estimate to $3.75 from $3.22 previously."
Teva Pharma (Nasdaq: TEVA): "1Q12 EPS estimate of $1.42 (vs previous $1.48);
2Q12 EPS estimate of $1.34 (vs previous $1.38); 3Q12 EPS estimate of $1.34 (vs
previous $1.32); and 4Q12 EPS estimate of $1.46 (vs previous $1.39)." (FY12 remains $5.57)
Warner Chilcott (Nasdaq: WCRX): "Following a review of our model, we are revising our 2012 EPS estimate to $3.68 (vs previous $3.64), with changes stemming from slight tweaks to our cost assumptions."
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Goldman Sachs Upgrades Tanger Factory Outlet Centers (SKT) to Neutral
- UPDATE: Bernstein Cuts BlackBerry (BBRY) to Underperform; Notes Weak BB10 Traction
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
